Digital Look

Welcome to Digital Look++,
you are not logged in

Advanced Search | Company A-Z | Feedback

HUTCHMED (China) Limited (HCM)

Sector:

Pharma and Biotech

Index:

FTSE AIM 100

290.00p

Change Today:

-14.00p
52 Week High: 326.00
52 Week Low: 173.60

Currency: UK Pounds
Shares Issued: 871.26m
Volume: 85,819

Market Cap: £2,526.64m
RiskGrade: 226

Trade now with Barclays Stockbrokers

Update - HUTCHMED (China) Limited is down today can you capitalise from spread betting? Find out more
Update - HUTCHMED (China) Limited is near the bottom of the FTSE AIM 100 - will it stay here? Have a look at HUTCHMED (China) Limited's chart Find out more

Latest ShareCast News

Hutchmed China to make several presentations at cancer research meeting

By Josh White

Date: Friday 05 Apr 2024

(Sharecast News) - Hutchmed China announced the upcoming presentation of new and updated data from various studies featuring compounds it had discovered on Friday, at the American Association of Cancer Research (AACR) annual meeting from 5 to 10 April in San Diego, California.

Read full story

News Channel

Hutchmed endometrial cancer treatment gets priority review in China

By Josh White

Date: Tuesday 02 Apr 2024

(Sharecast News) - Hutchmed China announced the acceptance and granting of priority review by the China National Medical Products Administration (NMPA) for a new drug application combining fruquintinib and sintilimab for the treatment of advanced endometrial cancer on Tuesday.

Read full story

News Channel

Hutchmed cancer treatment indication accepted for review in China

By Josh White

Date: Thursday 28 Mar 2024

(Sharecast News) - Hutchmed China announced a significant milestone in its cancer treatment work on Thursday, with the supplemental new drug application (sNDA) for savolitinib had been accepted for review by the China National Medical Products Administration (NMPA).

Read full story

News Channel

Hutchmed partner Inmagene exercises options over...	02-Feb-2024	ShareCast
Hutchmed's 'Elunate' approved under new Hong Kon...	30-Jan-2024	ShareCast
Hutchmed application for thrombocytopenia treatm...	11-Jan-2024	ShareCast
Hutchmed completes trial enrolment, keeps drugs ...	13-Dec-2023	ShareCast
Hutchmed completes trial enrolment, keeps drugs ...	13-Dec-2023	ShareCast
Hutchmed confirms new drug application for fruqu...	29-Sep-2023	ShareCast
Director dealings: IPF non-exec picks up shares,...	14-Sep-2023	ShareCast
Hutchmed reports progress on two oncology fronts	12-Sep-2023	ShareCast
Hutchmed tumour therapy candidate gets breakthro...	29-Aug-2023	ShareCast
Hutchmed meets all endpoints in platelet disorde...	21-Aug-2023	ShareCast
Hutchmed launches new phase one study in China	10-Jul-2023	ShareCast
Hutchmed China's colorectal cancer study to be p...	16-Jun-2023	ShareCast
US FDA gives priority to Hutchmed's colorectal c...	26-May-2023	ShareCast
Hutchmed's gastric cancer treatment accepted for...	18-Apr-2023	ShareCast
Hutchmed completes rolling FDA submission for co...	31-Mar-2023	ShareCast
Hutchmed enrols last patient in lymphoma treatme...	27-Feb-2023	ShareCast
Hutchmed China completes enrolment for solveplen...	03-Jan-2023	ShareCast

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

HCM Market Data

Currency	UK Pounds
Share Price	290.00p
Change Today	-14.00p
% Change	-4.61 %
52 Week High	326.00
52 Week Low	173.60
Volume	85,819
Shares Issued	871.26m
Market Cap	£2,526.64m
RiskGrade	226